Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Part of paid clinical trials in Bay Shore, New York.

Sponsor
Exelixis
Study ID
NCT07620574
Phase
PHASE3
Status
Enrolling By Invitation

Conditions

  • Cancer
  • Colorectal Cancer
  • Differentiated Thyroid Cancer (DTC)
  • Extra-Pancreatic NET (epNET)
  • Hepatocellular Carcinoma (HCC)
  • Non-Clear Cell Renal Cell Carcinoma (nccRCC)
  • Pancreatic Neuroendocrine Tumors (pNET)
  • Prostate Cancer
  • Renal Cell Carcinoma (RCC)

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cabozantinib — DRUG
    Administered as specified in the parent study.
  • Zanzalintinib — DRUG
    Administered as specified in the parent study.
  • Atezolizumab — DRUG
    Administered as specified in the parent study.
  • Nivolumab — DRUG
    Administered as specified in the parent study.
  • Abiraterone — DRUG
    Administered as specified in the parent study.
  • Prednisone — DRUG
    Administered as specified in the parent study.
  • Enzalutamide — DRUG
    Administered as specified in the parent study.

Study Details

The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.

Key Dates

First listed
Jun 2, 2026
Start date
Jul 30, 2026
Status verified
Aug 2026
Primary completion
May 31, 2030
Completion
May 31, 2030

Study Design

Enrollment
5,000 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cabozantinib/Zanzalintinib
    Depending on the study treatment received in the parent study, participants may receive cabozantinib alone or in combination with other agents; zanzalintinib alone or in combination with other agents, or comparator.

Primary Outcome Measure

Number of Participants With Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to 4 years (until the event resolves, returns to baseline, stabilizes, a new anticancer therapy is initiated, or the participant is lost to follow-up or withdraws consent, whichever occurs first) ]

Locations (2)

FacilityCityStateZIPSite coordinators
New York Cancer and Blood SpecialistsBay ShoreNew York11706-
Greater Dayton Cancer CenterKetteringOhio45409-

Find similar trials in Bay Shore, NY

Nationwide
Colorectal cancer trialsProstate cancer trialsOncology trialsGI oncology trialsProstate oncology trialsMen's health trialsUrology trials
By condition
Colorectal cancerProstate cancer
By specialty
OncologyGI oncologyProstate oncologyMen's healthUrology
By research site
New York Cancer and Blood Specialists· Bay Shore, NYGreater Dayton Cancer Center· Kettering, OH

Related Studies